サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1530913

デュシェンヌ型筋ジストロフィー市場：世界の産業分析、規模、シェア、成長、動向、2024～2034年予測

Duchenne Muscular Dystrophy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 167 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
デュシェンヌ型筋ジストロフィー市場：世界の産業分析、規模、シェア、成長、動向、2024～2034年予測
出版日: 2024年06月06日
発行: Transparency Market Research
ページ情報: 英文 167 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

デュシェンヌ型筋ジストロフィー市場-調査範囲

TMRの調査レポート「デュシェンヌ型筋ジストロフィーの世界市場」は、2024～2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018～2034年までの世界のデュシェンヌ型筋ジストロフィー市場の収益と予測を提供しています。また、2024～2034年までの世界のデュシェンヌ型筋ジストロフィー市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、デュシェンヌ型筋ジストロフィー市場を推察しました。

市場スナップショット
2023年の市場規模 22億米ドル
2034年の市場規模 74億米ドル
CAGR 11.7%

当レポートでは、世界のデュシェンヌ型筋ジストロフィー市場の競合情勢について調査しています。世界のデュシェンヌ型筋ジストロフィー市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界のデュシェンヌ型筋ジストロフィー市場における参入企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020～2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主要調査結果・発展
  • 市場金額予測：治療タイプ別、2020～2034年
    • 分子ベースの治療法
    • ステロイド療法
    • 非ステロイド性抗炎症薬（NSAID）
    • 理学療法
    • その他（手術等）
  • 市場の魅力分析：治療タイプ別

第7章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主要調査結果・発展
  • 市場金額予測：エンドユーザー別、2020～2034年
    • 病院
    • 専門クリニック
    • その他（研究機関等）
  • 市場の魅力分析：エンドユーザー別

第8章 世界の市場分析と予測：地域別

  • 主要調査結果
  • 市場金額予測：地域別、2020～2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第9章 北米の市場分析と予測

第10章 欧州の市場分析と予測

第11章 アジア太平洋の市場分析と予測

第12章 ラテンアメリカの市場分析と予測

第13章 中東・アフリカの市場分析と予測

第14章 競合情勢

  • 市場企業-競争マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Bristol Myers Squibb Company
    • GSK plc
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim
    • Sanofi
    • Sarepta Therapeutics, Inc.
図表

List of Tables

  • Table 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 02: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 03: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 04: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 05: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 06: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 07: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 09: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 10: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 11: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 12: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 13: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 15: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 18: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by Treatment Type, 2023
  • Figure 03: Global Duchenne Muscular Dystrophy Market Value Share, by Treatment Type, 2023
  • Figure 04: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by End-user, 2023
  • Figure 05: Global Duchenne Muscular Dystrophy Market Value Share, by End-user, 2023
  • Figure 06: Global Duchenne Muscular Dystrophy Market Value Share, by Region, 2023
  • Figure 07: Global Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 08: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 09: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 10: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 11: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 12: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 13: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 14: North America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 15: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country, 2023-2034
  • Figure 16: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 17: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 18: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 19: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 20: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 21: Europe Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 22: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 23: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 24: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 25: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 26: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 27: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 28: Asia Pacific Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 29: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 30: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 31: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 32: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 34: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 35: Latin America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 36: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 37: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 38: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 39: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 41: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 42: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 43: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 44: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 45: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 46: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 47: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 48: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL28145

Duchenne muscular dystrophy Market - Scope of Report

TMR's report on the global Duchenne muscular dystrophy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global Duchenne muscular dystrophy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Duchenne muscular dystrophy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Duchenne muscular dystrophy market.

Market Snapshot
Market Value in 2023US$ 2.2 Bn
Market Value in 2034US$ 7.4 Bn
CAGR11.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Duchenne muscular dystrophy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Duchenne muscular dystrophy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Duchenne muscular dystrophy market.

The report delves into the competitive landscape of the global Duchenne muscular dystrophy market. Key players operating in the global Duchenne muscular dystrophy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Duchenne muscular dystrophy market profiled in this report.

Key Questions Answered in Global Duchenne muscular dystrophy Market Report:

  • What is the sales/revenue generated by Duchenne muscular dystrophy across all regions during the forecast period?
  • What are the opportunities in the global Duchenne muscular dystrophy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Duchenne muscular dystrophy Market - Research Objectives and Research Approach

The comprehensive report on the global Duchenne muscular dystrophy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Duchenne muscular dystrophy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Duchenne muscular dystrophy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Duchenne Muscular Dystrophy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 6.3.1. Molecular-based Therapies
    • 6.3.2. Steroid Therapy
    • 6.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.3.4. Physical Therapy
    • 6.3.5. Others (Surgery, etc.)
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2020-2034
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others (Research Institutes, etc.)
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Duchenne Muscular Dystrophy Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 9.3.1. Molecular-based Therapies
    • 9.3.2. Steroid Therapy
    • 9.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 9.3.4. Physical Therapy
    • 9.3.5. Others (Surgery, etc.)
  • 9.4. Market Value Forecast, by End-user, 2020-2034
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others (Research Institutes, etc.)
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Treatment Type
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Duchenne Muscular Dystrophy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 10.3.1. Molecular-based Therapies
    • 10.3.2. Steroid Therapy
    • 10.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 10.3.4. Physical Therapy
    • 10.3.5. Others (Surgery, etc.)
  • 10.4. Market Value Forecast, by End-user, 2020-2034
    • 10.4.1. Hospitals
    • 10.4.2. Specialty Clinics
    • 10.4.3. Others (Research Institutes, etc.)
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Type
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Duchenne Muscular Dystrophy Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.3.1. Molecular-based Therapies
    • 11.3.2. Steroid Therapy
    • 11.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 11.3.4. Physical Therapy
    • 11.3.5. Others (Surgery, etc.)
  • 11.4. Market Value Forecast, by End-user, 2020-2034
    • 11.4.1. Hospitals
    • 11.4.2. Specialty Clinics
    • 11.4.3. Others (Research Institutes, etc.)
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment Type
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Duchenne Muscular Dystrophy Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.3.1. Molecular-based Therapies
    • 12.3.2. Steroid Therapy
    • 12.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 12.3.4. Physical Therapy
    • 12.3.5. Others (Surgery, etc.)
  • 12.4. Market Value Forecast, by End-user, 2020-2034
    • 12.4.1. Hospitals
    • 12.4.2. Specialty Clinics
    • 12.4.3. Others (Research Institutes, etc.)
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment Type
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Duchenne Muscular Dystrophy Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.3.1. Molecular-based Therapies
    • 13.3.2. Steroid Therapy
    • 13.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 13.3.4. Physical Therapy
    • 13.3.5. Others (Surgery, etc.)
  • 13.4. Market Value Forecast, by End-user, 2020-2034
    • 13.4.1. Hospitals
    • 13.4.2. Specialty Clinics
    • 13.4.3. Others (Research Institutes, etc.)
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment Type
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. Pfizer Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. F. Hoffmann-La Roche Ltd.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Mylan N.V.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Fresenius Kabi AG
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Hikma Pharmaceuticals plc
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Novartis AG
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Teva Pharmaceutical Industries Ltd.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Bristol Myers Squibb Company
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GSK plc
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Bayer AG
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Sun Pharmaceutical Industries Ltd.
      • 14.3.11.1. Company Overview
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Financial Overview
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Boehringer Ingelheim
      • 14.3.12.1. Company Overview
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. SWOT Analysis
      • 14.3.12.4. Financial Overview
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Sanofi
      • 14.3.13.1. Company Overview
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. SWOT Analysis
      • 14.3.13.4. Financial Overview
      • 14.3.13.5. Strategic Overview
    • 14.3.14. Sarepta Therapeutics, Inc.
      • 14.3.14.1. Company Overview
      • 14.3.14.2. Product Portfolio
      • 14.3.14.3. SWOT Analysis
      • 14.3.14.4. Financial Overview
      • 14.3.14.5. Strategic Overview